Drugmaker developing abuse-deterrent painkiller

The San Diego company that makes the powerful new prescription painkiller Zohydro is selling off its migraine therapy business to focus on developing abuse-resistant forms of Zohydro.

Zogenix Chief Executive Officer Roger Hawley said the sale will help the company focus on the launch of Zohydro ER while providing capital "to continue the development of two abuse-deterrent formulations" of the opioid.

The company announced in November it would pursue an abuse-deterrent form of the drug.

Health officials around the country worry addicts will crush Zohydro capsules and then snort or inject the drug to get high.

Citing such worries, Massachusetts Gov. Deval Patrick tried to ban the drug, but a blocked the state from enforcing the ban. Patrick has since announced new restrictions on the .

4 /5 (2 votes)
add to favorites email to friend print save as pdf

Related Stories

States revolt against powerful new painkiller

Apr 04, 2014

State officials fighting a well-publicized battle against heroin and prescription drug abuse are revolting against a powerful new painkiller that law enforcement and public health officials fear could worsen ...

Sen. Joe Manchin seeks to block new painkiller

Mar 11, 2014

U.S. Sen. Joe Manchin is calling on the government's top health official to overturn the approval of a powerful painkiller, arguing that the pill Zohydro could add to the national epidemic of prescription drug abuse.

Recommended for you

Have a cold? Don't ask your doctor for antibiotics

11 hours ago

Antibiotic resistance is a major threat to public health. Resistance makes it harder for physicians to treat infections and can increase the chance patients will die from an infection. What is more, the treatment ...

Powdered measles vaccine found safe in early clinical trials

Nov 25, 2014

A measles vaccine made of fine dry powder and delivered with a puff of air triggered no adverse side effects in early human testing and it is likely effective, according to a paper to be published November 28 in the journal ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.